Hey there friend Brett
Company management is often a subject of shareholder disappointment on HC threads, but maybe go a bit easy on the Imugene team. It's not been 14 years - nothing like it.
The current scientific projects came to Imugene through the reverse takeover/backdoor listing of Biolife Sciences - in October 2013. Prior to that, Imugene was totally different entity in every practical sense, and it had nothing to do with Immuno Oncology.
So we are really looking at 4 years and 5 months, not 14 years.
The progress since then has actually been pretty good for a Biotech, and the growing interest in IMU as an investment reflects a growing confidence in the science, solid management with excellent connections, a decrease in the perceived risk, and the very significant growth of Immuno Oncology worldwide.
Cheers
Dave
Add to My Watchlist
What is My Watchlist?
